Condensed Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating expenses:
Research and development	$ 1,979	$ 1,192	$ 6,345	$ 4,293
General and administrative	1,498	2,353	5,351	5,007
Total operating expenses	3,477	3,545	11,696	9,300
Total operating loss	(3,477)	(3,545)	(11,696)	(9,300)
Other income (expense):
Interest income	12	3	29	11
Loss from equity method investment in Galectin Sciences, LLC	(53)		(390)
Total other income (expense)	(41)	3	(361)	11
Net loss	(3,518)	(3,542)	(12,057)	(9,289)
Preferred stock dividends	(278)	(123)	(763)	(613)
Preferred stock accretion	(57)	(58)	(172)	(171)
Warrant modification				(8,763)
Net loss applicable to common stockholders	$ (3,853)	$ (3,723)	$ (12,992)	$ (18,836)
Net loss per common share - basic and diluted	$ (0.17)	$ (0.22)	$ (0.60)	$ (1.15)
Weighted average common shares outstanding - basic and diluted	22,051	16,988	21,732	16,438